Home > Publications database > Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease > print

001     290087
005     20240510175949.0
024 7 _ |a 10.3324/haematol.2023.284310
|2 doi
024 7 _ |a 0390-6078
|2 ISSN
024 7 _ |a 1592-8721
|2 ISSN
037 _ _ |a DKFZ-2024-00986
082 _ _ |a 610
100 1 _ |a Kayser, Sabine
|b 0
245 _ _ |a Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
260 _ _ |a Pavia
|c 2024
|b Ferrata Storti Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1715338456_25992
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 319H - Addenda (POF4-319H)
|0 G:(DE-HGF)POF4-319H
|c POF4-319H
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Sartor, Chiara
|b 1
700 1 _ |a Giglio, Fabio
|b 2
700 1 _ |a Bruno, Alessandro
|b 3
700 1 _ |a Webster, Jonathan
|b 4
700 1 _ |a Chiusolo, Patrizia
|b 5
700 1 _ |a Saraceni, Francesco
|b 6
700 1 _ |a Guerzoni, Selene
|b 7
700 1 _ |a Pochintesta, Lara
|b 8
700 1 _ |a Borlenghi, Erika
|b 9
700 1 _ |a Marconi, Giovanni
|b 10
700 1 _ |a Zacheo, Irene
|b 11
700 1 _ |a Cerrano, Marco
|b 12
700 1 _ |a Salutari, Prassede
|b 13
700 1 _ |a Restuccia, Francesco
|b 14
700 1 _ |a Abbenante, Mariachiara
|b 15
700 1 _ |a Levis, Mark J.
|b 16
700 1 _ |a Schlenk, Richard F.
|b 17
700 1 _ |a Papayannidis, Cristina
|b 18
773 _ _ |a 10.3324/haematol.2023.284310
|0 PERI:(DE-600)2805244-4
|n 5
|p 1385–1392
|t Haematologica
|v 109
|y 2024
|x 0390-6078
909 C O |o oai:inrepo02.dkfz.de:290087
|p VDB
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-319H
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-06-05T07:07:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-06-05T07:07:08Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2023-06-05T07:07:08Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-23
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-23
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-23
920 1 _ |0 I:(DE-He78)W010-20160331
|k W010
|l Klinische Studienzentrale
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)W010-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21